RxDoctor Payments DataLook up a doctor →

Timothy Ritter, MD

Gastroenterology · Southlake, TXNPI 1235115189

Payments from drug & device makers

$7,710,553in general payments, 2019–2025

Across 2,447 payments — averaging $3151.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$924K
  • Janssen Research & Development, LLC$871K
  • Takeda Pharmaceuticals U.S.A., Inc.$856K
  • Pfizer$786K
  • Eli Lilly$727K
  • Bristol Myers Squibb$528K
  • plus $3M from 49 others
$46,706in research payments, 2019–2025

Across 36 payments — averaging $1297.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$25K
  • Pfizer$14K
  • UCB, Inc.$5K
  • Sanofi US Services Inc.$2K
  • Gilead$1K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Gilead163$923,671
Janssen Research & Development, LLC103$870,936
Takeda Pharmaceuticals U.S.A., Inc.174$855,968
Pfizer(2 entities)368$785,672
Eli Lilly50$726,564
Bristol Myers Squibb75$528,137
Genentech, Inc.135$400,497
AbbVie(2 entities)390$399,190
Boehringer Ingelheim21$305,968
E.r. Squibb & Sons, L.L.C.88$279,035
Roche Products Limited88$236,691
Ironwood Pharmaceuticals, Inc18$235,599
Johnson & Johnson(2 entities)202$224,964
Teva Pharmaceuticals USA, Inc.26$214,949
Regeneron14$164,186
F. Hoffmann-la Roche AG17$124,631
Janssen Scientific Affairs, LLC116$114,474
Takeda2$95,040
Lilly USA, LLC121$89,654
Boehringer Ingelheim International GmbH5$28,008
Boehringer Ingelheim RCV GmbH & Co KG48$18,351
Sanofi US Services Inc.1$13,900
Shire North American Group Inc8$12,874
Merck22$10,638
Ferring Pharmaceuticals Inc.24$9,901
Gastrogpo, LLC16$7,759
Genentech USA, Inc.8$7,124
Aimmune Therapeutics, Inc.2$4,873
Intercept Pharmaceuticals, Inc.20$3,370
Pharmacosmos Therapeutics Inc.1$3,340
Novo Nordisk1$2,713
Ardelyx, Inc.5$2,087
Celltrion USA Inc.9$1,480
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC33$1,072
Regeneron Healthcare Solutions, Inc.15$1,065
Boehringer Ingelheim Pharma GmbH & Co.kg3$1,044
Hoffmann-la Roche Limited1$1,002
UCB Biosciences Inc.3$1,000
Fresenius Kabi USA, LLC2$915
Phathom Pharmaceuticals, Inc.15$914
Organon6$192
Medtronic1$161
Braintree Laboratories, Inc.5$159
Madrigal Pharmaceuticals1$138
Daiichi Sankyo Inc.6$115
AMAG Pharmaceuticals, Inc.2$111
Echosens North America, Inc.1$89
Covidien LP1$77
Sanofi3$76
Ipsen Biopharmaceuticals, Inc2$65
Amgen2$60
Evoke Pharma, Inc.1$20
UCB, Inc.1$16
Romark Laboratories, LC1$12
QOL Medical, LLC1$4

How this compares

$7,710,553 in reported general payments places this provider in the 95th percentile of 1,350 gastroenterology providers in Texas.

See all gastroenterology providers in Texas →

Medicare billing

Part B allowed, 2024
$99,380
Medicare patients
57
Services billed
3,451

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other gastroenterology in Southlake

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →